Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SYH2062 in Healthy Chinese Volunteers
NCT06842537Phase 1Recruiting
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypertension (HTN) comparing SYH2062 Injection with Placebo (2 arms). Primary endpoint: Number of Participants with Adverse Events (AEs) at 12 months. Started Mar 2025; status: recruiting.
02
Drugs
syh2062
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06842537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06842537.